Steven J. Kafka Sells 4,148 Shares of Foundation Medicine Inc (FMI) Stock

Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 4,148 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $65.71, for a total value of $272,565.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Steven J. Kafka also recently made the following trade(s):

  • On Tuesday, January 2nd, Steven J. Kafka sold 157 shares of Foundation Medicine stock. The stock was sold at an average price of $64.00, for a total value of $10,048.00.

Foundation Medicine Inc (NASDAQ FMI) traded down $0.60 during mid-day trading on Thursday, hitting $66.35. The stock had a trading volume of 89,631 shares, compared to its average volume of 326,135. Foundation Medicine Inc has a 1 year low of $17.50 and a 1 year high of $74.30. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. The company has a market cap of $2,410.00, a price-to-earnings ratio of -14.84 and a beta of -0.01.

Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. During the same period last year, the company posted ($0.90) EPS. The business’s quarterly revenue was up 45.0% on a year-over-year basis. equities analysts forecast that Foundation Medicine Inc will post -4.44 earnings per share for the current year.

Several brokerages recently issued reports on FMI. BidaskClub lowered Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research lowered Foundation Medicine from a “buy” rating to a “sell” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $45.33.

Several hedge funds have recently bought and sold shares of FMI. Legal & General Group Plc grew its stake in shares of Foundation Medicine by 8.6% in the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock valued at $138,000 after buying an additional 274 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Foundation Medicine by 3.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,747 shares of the company’s stock valued at $467,000 after buying an additional 341 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Foundation Medicine by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock valued at $2,449,000 after buying an additional 835 shares during the period. Wells Fargo & Company MN grew its stake in shares of Foundation Medicine by 8.8% in the 2nd quarter. Wells Fargo & Company MN now owns 11,510 shares of the company’s stock valued at $458,000 after buying an additional 931 shares during the period. Finally, Teachers Advisors LLC grew its stake in shares of Foundation Medicine by 5.5% in the 2nd quarter. Teachers Advisors LLC now owns 25,728 shares of the company’s stock valued at $1,023,000 after buying an additional 1,341 shares during the period. 32.68% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Steven J. Kafka Sells 4,148 Shares of Foundation Medicine Inc (FMI) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/18/steven-j-kafka-sells-4148-shares-of-foundation-medicine-inc-fmi-stock.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply